此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

OBIZUR 在韩国治疗成人获得性 A 型血友病 (AHA) 的研究

2026年11月4日 更新者:Takeda

OBIZUR注射液[Susoctocog Alpha(猪抗血友病因子VIII,重组)]在韩国的批准适应症的上市后监测(使用结果监测)

Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.

The main aim of the study is to learn how safe OBIZUR is in adults with AHA.

Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.

The treatment of the participants will be determined by the treating physicians.

During the study, data already existing in the participants' medical record and new data will be collected.

研究概览

地位

招聘中

干预/治疗

详细说明

This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.

研究类型

观察性的

注册 (估计的)

11

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Seoul、韩国、06591
        • 招聘中
        • The Catholic University of Korea, Seoul St. Mary's Hospital
        • 接触:
        • 首席研究员:
          • Jae-ho Yoon
      • Seoul、韩国、05278
        • 招聘中
        • Kyung Hee University Hospital at Gangdong
        • 接触:
        • 首席研究员:
          • Young Shil Park, Ph.D
      • Seoul、韩国、07804
        • 招聘中
        • Ewha Womans University Medical Center
        • 接触:
        • 首席研究员:
          • Jae-joon Han
      • Ulsan、韩国、44033
        • 招聘中
        • Ulsan University Hospital
        • 首席研究员:
          • Yoo Jin Lee
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Participants with AHA who are receiving OBIZUR Injection or initiate OBIZUR Injection treatment for the first time will be enrolled.

描述

Inclusion Criteria:

  • Participants with AHA.
  • Participants who are determined to have the clinical need to receive Obizur treatment.
  • Participants aged 18 years or older at time of initiation of Obizur treatment.
  • Participants agreed to participate in the study and voluntarily signed the informed consent.

Exclusion Criteria:

  • Participants with hypersensitivity to any of the components of this drug.
  • Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
  • Participants for whom Obizur treatment is contraindicated as per product label.
  • Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:OTHER

队列和干预

团体/队列
干预/治疗
All Participants

Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice.

OBIZUR injection.

其他名称:
  • TAK-672
  • 苏索克托科阿尔法
  • 猪抗血友病因子 VIII,重组

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI)
大体时间:Up to 3 months

Number of participants with AEs, causality to AEs, SAEs and AESI will be reported. The investigator will assess the causal relationship (causality) between the medicinal product and the AE using his/her clinical expertise and judgment.

Up to 3 months
Number of Participants With Expected/Unexpected AEs and SAEs
大体时间:Up to 3 months

Unexpected AE is defined as AE that differs from the information in the product label in nature, severity, specificity, or outcome.

Up to 3 months
Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRs
大体时间:Up to 3 months

An ADR refers to any undesirable and unintended reaction which occurs during or following the administration of the drug, and in which a causal relationship with the drug cannot be ruled out. In the event that a causal relationship with the drug remains unknown amongst reported adverse events, such reaction shall be considered an adverse drug reaction. Serious ADR means noxious or unintended response to a drug that occurs at any dosage and that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death. Unexpected ADRs is defined as ADR that differs from the information in the product label in nature, severity, specificity, or outcome.

Up to 3 months
Number of Participants With Special Situation Report (SSR)
大体时间:Up to 3 months

SSR include following events: Pregnancy: any case in which a pregnancy participant is exposed to a Takeda Product or in which a female participant or partner of a male participant becomes pregnant following Takeda product.; Breastfeeding: infant exposure from breast milk; Overdose: all information of any accidental or intentional overdose; Drug abuse, misuse or medication error: all information on medicinal product (MP) abuse, misuse of medication error (potential or actual); Suspected transmission of infectious agent: Suspected (in sense of confirmed or potential) transmission of infectious agent by a MP; Lack of efficacy of Takeda Product; accidental/occupational exposure; Use outside the terms of the marketing authorization, also known as "off-label" and "off-label use"; Use of falsified and counterfeit MP; Drug-drug and drug-food interactions; Inadvertent or accidental exposure with or without an AE; Unintended benefit.

Up to 3 months

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants With Overall Bleeding Control
大体时间:Up to 3 months

Overall Bleeding Control will be determined as either bleeding stopped or did not stop.

Up to 3 months
Time to Achieve Bleeding Control With OBIZUR Injection
大体时间:Up to 3 months

Time to achieve bleeding control will be assessed from initiation of OBIZUR Injection (start time) to the time to achieve bleeding control (stop time).

Up to 3 months
Number of OBIZUR Injection Infusion Required to Achieve Bleeding Control
大体时间:Up to 3 months

Number of OBIZUR injection infusion required to achieve bleeding control will be reported.

Up to 3 months
Dose of OBIZUR Required to Stop the Bleeding
大体时间:Up to 3 months

OBIZUR dose required to stop the bleeding will be reported.

Up to 3 months
Percentage of Participants With Bleeding Events
大体时间:Up to 3 months

Bleeding events will be evaluated and reported as re-bleed, concurrent bleed and subsequent bleed. Re-bleed: if it occurs in the same anatomical location and within 72 hours of the resolution of the previous bleeding. Concurrent bleed: if it occurs at the same time (that is, during treatment or within 72 hours of resolution) as previous bleed but at a different anatomical location. Subsequent bleed: if it is a new bleed occurring 72 hours after the resolution of the previous bleed (either in the same anatomical location or in a new one).

Up to 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Study Director、Takeda

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年7月22日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2024年8月9日

首先提交符合 QC 标准的

2024年8月9日

首次发布 (实际的)

2024年8月13日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 共享访问标准

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅